Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Glimepiride I.P. 1mg + Voglibose I.P. 0.2mg + Metformin HCL I.P. 500mg Bi-Layered Tablets
Therapeutic Category
Antidiabetic, Diabetic, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*15
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Vogliviga GM1/0.2 Tablet combines Glimepiride 1mg, Voglibose 0.2mg, and Metformin 500mg in a bi-layered tablet designed to manage type 2 diabetes effectively. Glimepiride helps increase insulin release from the pancreas, Voglibose reduces post-meal blood sugar spikes by delaying carbohydrate absorption, and Metformin improves insulin sensitivity and reduces glucose production in the liver. This combination works on multiple fronts to control blood sugar levels efficiently throughout the day.
Common side effects may include gastrointestinal discomfort such as nausea, abdominal bloating, flatulence, and diarrhea. There is a risk of hypoglycemia, particularly if meals are skipped or dosage is not followed correctly. Long-term use of Metformin may cause vitamin B12 deficiency in some patients.
This medication is indicated for the treatment of type 2 diabetes mellitus, especially for patients who need better control of both fasting and postprandial blood glucose levels.
Not suitable for patients with type 1 diabetes, severe liver or kidney disease, or diabetic ketoacidosis. Regular monitoring of blood sugar levels is necessary during treatment. Alcohol consumption should be avoided. Follow your doctor’s advice strictly.
Store in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children.
Composition : Metformin (500mg) SR + Voglibose (0.3mg) Tablet
Composition : Metformin (500mg) SR + Voglibose (0.2mg) Bilayered Smart Tablet
Composition : Glimepiride (2mg) + Metformin (500mg) SR + Voglibose (0.2mg) Bilayered Smart Tablet
Composition : Rosuvastatin 10 mg tablet
Composition : Rosuvastatin (20mg) tablet
Composition : Rosuvastatin 40 mg tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 20 mg + aspirin 75 mg tablet
Composition : Atorvastatin Calcium I.P. 10mg Tablets
Composition : Atorvastatin Calcium I.P. 20mg Tablets
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Glimepiride 1mg + Voglibose 0.2mg + Metformin Hydrochloride Tablet has strong demand in the diabetology, endocrinology, and general medicine segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on anti-diabetic and chronic care portfolios.
Medical distributors and agencies can benefit from consistent demand for Type 2 diabetes management under medical supervision. Glimepiride 1mg is a sulfonylurea that stimulates the pancreas to release insulin, helping lower blood glucose levels Voglibose 0.2mg is an alpha-glucosidase inhibitor that delays the digestion and absorption of carbohydrates, helping reduce postprandial (after-meal) blood glucose spikes Metformin Hydrochloride is a biguanide anti-diabetic agent that reduces hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose utilization This triple-drug combination provides complementary mechanisms of action to improve fasting and postprandial blood glucose control in adults with Type 2 Diabetes Mellitus, along with diet and regular exercise Commonly prescribed for patients whose blood glucose levels are not adequately controlled with dual-drug therapy, helping reduce the risk of long-term diabetes-related complications affecting the heart, kidneys, eyes, and nerves Oral tablet formulation supports convenient administration and improves treatment adherence. Patients should be monitored regularly for blood glucose, HbA1c, kidney function, and signs of hypoglycemia, especially due to the sulfonylurea component Frequently utilized in diabetology clinics, endocrinology departments, general medicine practices, and hospitals Widely prescribed by diabetologists, endocrinologists, and general physicians for long-term management of Type 2 Diabetes Mellitus This strengthens a comprehensive anti-diabetic and chronic care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Glimepiride 1mg + Voglibose 0.2mg + Metformin Hydrochloride Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from consistent prescription demand, expanding diabetes care market opportunities, long-term therapy requirements, reliable supply chain support, repeat business, and attractive margins in the anti-diabetic segment.
Interested distributors, stockists, wholesalers, and institutional suppliers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality anti-diabetic pharmaceutical products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.